Novartis Gets CDSCO Panel Nod to study Remibrutinib to treat chronic spontaneous urticaria Dr. Divya Colin8 Dec 2023 6:00 PM ISTNew Delhi: The drug major Novartis has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Novartis gets USFDA nod for Fabhalta for adults with paroxysmal nocturnal hemoglobinuria Ruchika Sharma7 Dec 2023 11:43 AM ISTBasel: Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved Fabhalta (iptacopan) as the first oral monotherapy for the...
Novartis raises sales growth target to 5 percent a year through 2027 Ruchika Sharma28 Nov 2023 3:30 PM ISTFrankfurt: Novartis has dialled up its sales growth target to 5% per year until 2027, citing demand for innovative drugs after the spin off of...
Atrasentan found superior to placebo for proteinuria reduction in the Phase 3 Trial for IgA Nephropathy. Dr Kartikeya Kohli4 Nov 2023 11:15 AM ISTIgA nephropathy (IgAN) is an autoimmune disorder wherein clusters of antibodies get deposited in the kidneys, leading to inflammation and damage to...
Novartis wins USFDA nod for Cosentyx to treat hidradenitis suppurativa in adults Ruchika Sharma1 Nov 2023 2:00 PM ISTBasel: Novartis has announced that the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) to treat moderate to severe...
CDSCO Panel approves Novartis proposal to update package insert of Secukinumab Dr. Divya Colin25 Oct 2023 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Center Drug Standard Control Organisation (CDSCO) has granted approval to drug...
FDA approves intravenous Secukinumab for Rheumatic diseases Dr. Kamal Kant Kohli11 Oct 2023 11:45 AM ISTThe US Food and Drug Administration (FDA) has approved an intravenous formulation of Secukinumab for patients with psoriatic arthritis, ankylosing...
Novartis Cosentyx IV formulation for rheumatic diseases bags USFDA okay Ruchika Sharma10 Oct 2023 1:30 PM ISTThe IV formulation of Cosentyx offers patients a monthly 30-minute, weight-based dosing option, requiring no pre-medication and no lab monitoring.
Novartis concludes Sandoz spin-off Ruchika Sharma5 Oct 2023 10:30 AM ISTBasel: Novartis has completed the Spin-off of Sandoz, its Generics and Biosimilars business, through a dividend-in-kind distribution to holders of...
BeiGene regains full rights from Novartis for Anti-PD-1 antibody Tevimbra Ruchika Sharma20 Sept 2023 5:31 PM ISTBasel: BeiGene, Ltd., a global biotechnology company, has announced that it has entered into an agreement with Novartis to regain worldwide...
Novartis Kisqali reduced cancer recurrence risk while maintaining quality of life in patients diagnosed with early breast cancer Ruchika Sharma18 Sept 2023 12:30 PM ISTBasel: Novartis has presented new patient-reported outcomes (PRO) data from the Phase III NATALEE trial at the European Society for Medical Oncology...
Novartis shareholders approve proposed 100 percent Spinoff of Sandoz Ruchika Sharma16 Sept 2023 3:30 PM ISTBasel: Novartis shareholders approved the proposed 100% Spin-off of Sandoz, the Generics and Biosimilars business of Novartis in an Extraordinary...
